2013 Volume 123 Issue 8 Pages 1527-1536
The increased use of molecular-targeted cancer drugs results in challenges for the management of dermatological adverse reactions. We conducted an online survey of dermatologists in Japan to analyze these challenges. Methods: Two questionnaires were distributed online from December 2011 to January 2012 to dermatologists subscribing to CareNet. Results: The primary survey on the treatment experience of molecular-targeted drug-induced dermatological reactions revealed that 88.5% (154/174) of hospital doctors and 61.0% (61/100) of general practitioners had relevant experience. A secondary survey included a wider range of dermatologists with treatment experience and found that 85% of practitioners had treated ≤5 patients while many hospital doctors had approximately 10 patients annually. Nearly 90% of the patients treated by hospital dermatologists were within-hospital referrals; about 70% of patients treated by practitioners sought treatment spontaneously. The primary drugs of choice for the majority were topical steroids, oral tetracyclines and topical moisturizers. Discussion: Although many dermatologists already manage dermatological disorders associated with molecular-targeted drugs, their cooperation with oncology departments is not fully established. To facilitate supportive care for patients, dermatologists should recognize their crucial role in developing and providing effective management strategies and should strive for further studies and closer cooperation with the oncology professionals to optimize this role.
